|
KMID : 4412620180240010002
|
|
Clinical Hypertension
2018 Volume.24 No. 1 p.2 ~ p.2
|
|
|
Efficacy and safety of azilsartan medoxomil, an angiotensin receptor blocker, in Korean patients with essential hypertension
|
|
Juhasz Attila
Wu Jingtao
Hisada Michie
Tsukada Tomoka
Jeong Myung-Ho
|
|
|
Abstract
|
|
|
Background: This was a phase 3, randomized, double-blind, placebo-controlled study.
Methods: Adult Korean patients with essential hypertension and a baseline mean sitting clinic systolic blood pressure (scSBP) ≥150 and ≤180 mmHg were randomized to 6-week treatment with placebo (n =?65), azilsartan medoxomil (AZL-M) 40 mg (n =?132), or AZL-M 80 mg (n =?131). The primary endpoint was the change from baseline to week 6 in trough scSBP.
Results: The least-squares mean (standard error) change from baseline in trough scSBP in the placebo, AZL-M 40-mg, and 80-mg groups at week 6 were ??8.8 (2.00), ??22.1 (1.41), and ??23.7 (1.40) mmHg, respectively (p
Conclusions: Results of this study confirm a positive benefit-risk profile of AZL-M for essential hypertension in Korean adults.
Trial registration: Clinicaltrial.gov; identifier number: NCT02203916. Registered July 28, 2014 (retrospectively registered)
|
|
|
KEYWORD
|
|
|
Hypertension, Azilsartan medoxomil, Angiotensin II receptor antagonist, Blood pressure, Korea
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
 
|
|